Up and Coming
This feature highlights changes in clinical trial organizations’ personnel.
Sophie Biguenet has been named chief medical officer of Abivax. Prior to this appointment, Biguenet was chief medical officer of Swiss clinical-stage biotechnology company Versantis.
Algernon Pharmaceuticals has appointed Christopher Bryan to vice president of research and operations. Bryan was a medical science liaison at Medicure before joining Algernon last year as a senior scientist. Another new appointment at Algernon includes Ahmad Khalil, who has been named chief medical officer. Khalil was most recently the former sponsor medical monitor for two of Algernon’s clinical trial programs.
Aro Biotherapeutics has hired Adam Dinerman to serve as executive director and head of chemistry, manufacturing and controls (CMC). Prior to this appointment, Dinerman was director and CMC team leader at Johnson & Johnson. John Liu, former director of biology at NGM Biopharmaceuticals, has also been tapped by Aro to serve as vice president of biology.
Shreehas Tambe has been promoted from his most recent role of chief operating officer to deputy CEO at the company.
John R. Beaver, the executive vice president and chief operating officer of BIOLASE, has been promoted to CEO. Before joining BIOLASE in 2017, Beaver was the chief financial officer at Silicor Materials.
Alan Holmes has been named senior director of fibrosis at Engitix. Most recently, Holmes was director of drug target identification at UCB. John Prime, former senior bioinformatics scientist and site lead at Horizon Discovery, has been hired by Engitix to take on the role of director of computational biology.
Usama Malik has taken the helm of Fore Biotherapeutics as its newest CEO. Malik was previously the chief financial officer of Immunomedics.
Michael Parini has been named chief operating officer of Freeline Therapeutics. Parini is the former executive vice president and chief administrative, legal and business development officer for Vertex Pharmaceuticals.
Magnus Korsgren has been named head of R&D at Hansa Biopharma. Korsgren was previously a senior medical director at Ferring Pharmaceuticals.
Khalil Salman has been named director of clinical informatics at Hyperfine Research. Salman most recently served as assistant professor of medical imaging and director of medical imaging informatics at the University of Arizona and Banner Health.
Jeroen Rovers, former managing director of oncology vaccine company DCprime, has been named chief medical officer of Immunicum.
Kadmon has appointed Simon Cooper to the role of chief medical officer. Most recently, Cooper served as chief medical officer of Anokion.
Richard Lee has been tapped by Kira Pharma to serve as the company’s chief medical officer. Recently, Lee was head of hematology at Alexion.
Former CEO of Ironwood Pharmaceuticals, Mark Mallon, has been named CEO of NeoGenomics, a post he will assume April 19.
NeoImmuneTech’s chief scientific officer role has been taken on by Byung Ha Lee, who most recently served as director of R&D at the company. Prior to joining NeoImmuneTech in 2016, Lee was senior manager at Genexine.
Christophe Bourdon has been named CEO of Orphazyme. Prior to taking the helm at the late-stage biopharmaceutical company, Bourdon was senior vice president and general manager of U.S. oncology business at Amgen.
Panthera Biopartners has appointed Matt Cooper to general manager of oncology. Cooper was most recently chief operating officer of DATA-CAN, the Health Data Research Hub for Cancer.
Jordan Dubow has signed on as chief medical officer for Paragon Biosciences. Formerly, Dubow was chief medical officer at Avadel Pharmaceuticals.
Hermes Garbán, former head of therapeutics discovery and development at ImmunityBio, has been named chief medical officer of Vincerx Pharma. Hans-Georg Lerche has also been added to Vincerx’s staff, appointed to chief scientific officer. Most recently, Lerche served as a distinguished fellow in Bayer’s postdoctoral pharmaceuticals R&D program.